Vanguard Global Advisers
PRME icon

Vanguard Global Advisers’s Prime Medicine PRME Stock Holding History

Vanguard Global Advisers’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163K Hold
44,269
– – ﹤0.01% 2577
2026
Q1 		$154K Buy
+44,269
New +$168K ﹤0.01% 2552

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Global Advisers's PRME Position: Q2 2026 in Review

Vanguard Global Advisers held its Prime Medicine (PRME) position steady in Q2 2026 at 44,269 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Vanguard Global Advisers first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Vanguard Global Advisers held 44,269 shares of Prime Medicine worth $163K as of Q2 2026.
  • Vanguard Global Advisers left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2577 holding.
  • Vanguard Global Advisers first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.